公开(公告)号：WO2023278373A2

公开(公告)日：2023-01-05

申请号：PCT/US2022/035211

申请日：2022-06-28

申请人： VST LLC DBA MEDGENE LABS

发明人： YOUNG, Alan, John

IPC分类号： A61K39/12 ,  A61K9/00 ,  A61P31/12 ,  C07K14/08 ,  A61K2039/54 ,  A61K2039/541 ,  A61K2039/545 ,  A61K2039/55566 ,  A61P31/14 ,  C07K14/005 ,  C12N2770/16022 ,  C12N2770/16034 ,  C12N2770/16051 ,  C12N2770/16071

摘要： The present invention describes immunogenic compositions containing immunogenic polypeptides of Sapovirus, including immunogenic compositions containing antigens other than Sapovirus antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating a Sapovirus infection are also described.

公开(公告)号：WO2022261297A2

公开(公告)日：2022-12-15

申请号：PCT/US2022/032799

申请日：2022-06-09

申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

发明人： ROSS, Ted M. ,  ALLEN, James D.

IPC分类号： A61K39/12 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/55566 ,  A61K39/145 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16171

摘要： Provided herein are non-naturally occurring, broadly reactive antigens derived from influenza viruses that are immunogenic and capable of eliciting a broadly reactive immune response, e.g., a broadly reactive neutralizing antibody response, directed against influenza virus antigens following introduction into a subject. Also provided are non-naturally, broadly reactive immunogens, vaccines, virus particles, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a human or non-human subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise broadly reactive hemagglutinin (HA) protein antigens or soluble HA protein antigens of influenza virus strains, such as H1 or H3.

公开(公告)号：WO2022200582A1

公开(公告)日：2022-09-29

申请号：PCT/EP2022/057945

申请日：2022-03-25

申请人： GLAXOSMITHKLINE BIOLOGICALS SA ,  UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： VASSILEV, Ventzislav Bojidarov ,  MALLETT, Corey ,  ROUXEL, Ronan ,  BLAIS, Normand ,  KANEKIYO, Masaru ,  GRAHAM, Barney, Scott

IPC分类号： A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61P31/16 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55566 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/735 ,  C12N2760/16122 ,  C12N2760/16134

摘要： The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.

公开(公告)号：WO2021244996A1

公开(公告)日：2021-12-09

申请号：PCT/EP2021/064471

申请日：2021-05-30

申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. ,  CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN

发明人： SEEBERGER, Peter ,  KAPLONEK, Paulina ,  SANDER, Leif, Erik ,  BROECKER, Felix

IPC分类号： A61K39/09 ,  A61K31/04 ,  A61K39/00 ,  A61K2039/55511 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/572 ,  A61K2039/6037 ,  A61K39/092 ,  A61P31/04

摘要： The present invention relates to a vaccine comprising at least one glycoconjugate of synthetic Streptococcus pneumoniae oligosaccharides and a carrier protein, and at least one agonist or activator of toll-like receptors such as TLR1, 2, 4, 6, 7, 8, or 9, wherein the at least one glycoconjugate and the at least one adjuvant are encapsulated in biodegradable polymer particles. The vaccine of present invention is useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae, in particular Streptococcus pneumoniae serotype 3.

公开(公告)号：WO2021207599A1

公开(公告)日：2021-10-14

申请号：PCT/US2021/026577

申请日：2021-04-09

申请人： AKSTON BIOSCIENCES CORPORATION

发明人： ZION, Todd C. ,  LANCASTER, Thomas M. ,  SATHIYASEELAN, Thillainayagam ,  HUANG, Kexin

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61P31/14 ,  A61K38/00 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/6031 ,  A61K2039/6056 ,  A61K2039/6075 ,  A61K2039/62 ,  A61K39/215 ,  C07K14/165 ,  C07K2319/30 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N7/00

摘要： The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (CQVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naive patients to produce antibodies to the S ARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

公开(公告)号：WO2023059857A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/045992

申请日：2022-10-07

申请人： SANOFI PASTEUR INC.

发明人： ALEFANTIS, Timothy ,  BARRO, Mario ,  BYERS, Anthony ,  DAVIDSON, Philip ,  GIEL-MOLONEY, Maryann ,  GILBERT, Philippe-Alexandre ,  KLEANTHOUS, Harold ,  NAIK, Armaghan ,  PUGACHEV, Konstantin ,  SRIDHAR, Saranya ,  WARREN, William ,  ZELDOVICH, Konstantin

IPC分类号： A61K39/12 ,  A61P31/16 ,  G16H50/80 ,  A61K39/00 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/70 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16222 ,  C12N2760/16234 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70

摘要： Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

公开(公告)号：WO2023274860A1

公开(公告)日：2023-01-05

申请号：PCT/EP2022/067299

申请日：2022-06-24

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： BLAIS, Normand ,  SACCONNAY, Lionel ,  VASSILEV, Ventzislav Bojidarov

IPC分类号： A61K39/12 ,  A61P31/16 ,  A61K39/00 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  C12N2760/16222 ,  C12N2760/16234

摘要： Recombinant influenza B strain haemagglutinin antigens, polynucleotides encoding the antigens and immunogenic compositions comprising the antigens and polynucleotides.

公开(公告)号：WO2022233629A1

公开(公告)日：2022-11-10

申请号：PCT/EP2022/060941

申请日：2022-04-25

申请人： HIPRA SCIENTIFIC, S.L.U. ,  LABORATORIOS HIPRA, S.A.

发明人： BARREIRO VAZQUEZ, Antonio ,  PRENAFETA AMARGOS, Antoni ,  FERRER SOLER, Laura ,  GONZALEZ GONZALEZ, Luis ,  PUIGVERT MOLAS, Ester ,  PALMADA COLOMER, Jordi ,  PRAT CABAÑAS, Maria Teresa ,  GARRIGA ALSINA, Carmen

IPC分类号： A61K39/12 ,  A61K39/295 ,  A61P31/14 ,  A61K2039/55566 ,  A61K2039/55577 ,  C07K2319/00 ,  C12N2770/20034 ,  C12N2770/20071

摘要： The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor- binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

公开(公告)号：WO2022214685A2

公开(公告)日：2022-10-13

申请号：PCT/EP2022/059502

申请日：2022-04-08

申请人： VALNEVA SE

发明人： LUNDBERG, Urban ,  MEINKE, Andreas ,  PERUGI, Fabien

IPC分类号： A61K39/12 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61P31/14 ,  C12N2760/18334

摘要： The present invention relates to a vaccine composition for preventing and/or treating a respiratory system infection such as a human metapneumovirus infection of the respiratory system. This vaccine composition comprises two or more modified human metapneumovirus (hMPV) F proteins or variants thereof provided in a pre-fusion and/or post-fusion conformation form.

公开(公告)号：WO2022018576A1

公开(公告)日：2022-01-27

申请号：PCT/IB2021/056318

申请日：2021-07-14

申请人： PHIBRO ANIMAL HEALTH CORPORATION ,  FINGER, Avner ,  KHINICH, Yevgeny

发明人： KHINICH, Yevgeny ,  FINGER, Avner

IPC分类号： A61K39/12 ,  A61K39/145 ,  A61P31/16 ,  A61K2039/55566 ,  C12N2760/16134

摘要： Vaccine formulations comprising polyglycerol polyricinoleate (PGPR) are disclosed. Certain disclosed exemplary vaccine formulations comprised an aqueous phase comprising inactivated bacteria and/or viruses, and/or bacterial and/or viral antigens. One particular embodiment comprised an inactivated H9N2 PGPR emulsion-based vaccine for day-old chicks. Disclosed PGPR-based vaccine formulations can be administered alone, or in combination with or as a composition including a second standard fast release vaccine. Disclosed vaccines delay antigen release, and therefore delay an immune response in a subject receiving the vaccine, typically by 7 - 35 days. The present invention also concerns a method for vaccinating a subject, such as poultry or fish, with disclosed vaccine formulations, as well as a method for making PGPR-based vaccine formulations.